Orchid Pharma receives DCGI approval for combination of Cefepime and Enmetazobactam

DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable

Jemperli trial continues to show positive results for deficient (dMMR) rectal cancer

Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response

GSK disagrees with ruling by the Delaware State Court on Zantac (ranitidine) litigation

Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims

AstraZeneca completes acquisition of Fusion Pharmaceuticals

This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs

Moderna & Merck announce 3-year data for mRNA-4157 in combination with Keytruda

The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer

Aurigene Pharmaceutical opens biologics facility in Genome Valley, Hyderabad

The state-of-the-art facility is equipped with best-in-class equipment and control systems

Pfizer’s ADCETRIS regimen produces clinically meaningful improvement in overall survival in patients with DLBCL

Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen

NTPC, Tata Memorial Centre launch cancer awareness initiative

The cancer screening and awareness camp will run for four months in the Mira Bhayander Region, benefiting approximately 5,000 police personnel

Merck Specialities’ unique initiative to raise bladder cancer awareness

Takeda and Pfizer announce results from Positive Phase 3 HD21 trial of additional ADCETRIS combination in frontline hodgkin lymphoma

The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas